Please login to the form below

Not currently logged in
Email:
Password:

Bayer president Andreas Fibig set to depart

Will become CEO of International Flavors & Fragrances

Andreas-Fibig-BayerBayer Healthcare's president Andrea Fibig is to leave to become CEO of International Flavors & Fragrances (IFF).

Fibig has served as president of Bayer Healthcare since 2008, during which time he has been head of the company's pharmaceuticals division and a member of the executive committee.

The appointment at IFF marks a departure for Fibig who has been in the pharma industry since the early 1980s, serving at Schering and Boehringer Ingelheim in his early years.

In 2000 he went on to serve as present of Pharmacia & Upjohn's operations in Germany before joining Pfizer as president for its operations in Latin America, Africa and the Middle East and then serving as senior VP and general manager for Pfizer in the US.

This experience in the US will benefit Fibig in his first CEO position as he takes over from Doug Tough at New York-based IFF, which develops and creates flavors and fragrances for consumer products.

Tough commented that Fibig “brings the right combination of experience and skills”.

“He has led businesses with an international footprint similar to ours, has firsthand experience in key emerging markets where we see further opportunity, and understands the critical importance of science-based research in driving innovation and competitiveness,” he added.

Tough also remarked that Fibig knows IFF well due to serving as a board member since 2011.

As for who will replace Fibig at Bayer, the company stated a successor will be announced “in a few days”.

29th May 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....

Infographics